{"transactions":[{"id":683711,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":1360544,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The pre-funded warrant has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1360544,"derivative":{"exercise_price":0.001,"exercise_date":"2026-08-16","underlying":"Common Stock","underlying_shares":1360544},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683710,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series F Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":170068,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":170068,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":170068},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683709,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series E Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":170068,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":170068,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":170068},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683708,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series F Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":1360544,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1360544,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":1360544},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683707,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series E Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":1360544,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1360544,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":1360544},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683706,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Common Stock","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":170068,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":292631,"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":940539,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T01:46:39.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001279191-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000127919126000001/primary_doc.xml","form_type":"4"}},{"id":947022,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T01:00:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":37500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001493152-26-000698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000698/ownership.xml","form_type":"4"}},{"id":958305,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":78740,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":78740,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":78740},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958304,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":78740,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":12.7,"underlying":"Common Stock","underlying_shares":78740},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958303,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series D Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958302,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series C Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958301,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series D Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":490196,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":490496,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":490496},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958300,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series C Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":490196,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":490496,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":490196},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958299,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Common Stock","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":122563,"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958298,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Common Stock","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":490196,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":490255,"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":1093929,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:11:17.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2026-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007736","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007736/section16.xml","form_type":"4"}},{"id":1296492,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President, CEO and Chairman"}}],"security":"Warrant (Right to Buy)","published_at":"2025-01-23T22:02:08.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":787402,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":787402,"derivative":{"exercise_price":1.27,"underlying":"Common Stock","underlying_shares":787402},"source":{"system":"sec-edgar","filing":"0001654954-25-000691","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000691/section16.xml","form_type":"4"}},{"id":1296491,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2025-01-23T22:02:08.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":787402,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":799508,"source":{"system":"sec-edgar","filing":"0001654954-25-000691","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000691/section16.xml","form_type":"4"}},{"id":1303561,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-14T23:50:31.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":45000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001654954-25-000398","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000398/section16.xml","form_type":"4"}},{"id":1334919,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T01:07:26.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015476","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015476/section16.xml","form_type":"4"}},{"id":1438314,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2024-08-08T23:43:25.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":16660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors.  The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve\nExercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the \"Topline Data Announcement\"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029."}],"balance_after":16660,"derivative":{"exercise_price":4.5,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":16660},"source":{"system":"sec-edgar","filing":"0001654954-24-010193","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010193/section16.xml","form_type":"4"}},{"id":1438313,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2024-08-08T23:43:25.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":31654,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors.  The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The pre-funded warrant has no expiration date."}],"balance_after":31654,"derivative":{"exercise_price":0.01,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":31654},"source":{"system":"sec-edgar","filing":"0001654954-24-010193","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010193/section16.xml","form_type":"4"}},{"id":1438312,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-08T23:43:25.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":1666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors.  The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The aggregate number of shares of common stock previously reported as 1,495, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024."}],"balance_after":1667,"source":{"system":"sec-edgar","filing":"0001654954-24-010193","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010193/section16.xml","form_type":"4"}},{"id":1685683,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-06T02:02:58.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12-month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12-month anniversary of the grant date."}],"balance_after":125000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001654954-24-000299","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000299/section16.xml","form_type":"4"}},{"id":2237062,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T01:28:38.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008238","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008238/section16.xml","form_type":"4"}},{"id":2444436,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":57859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":57859,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":57859},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444435,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":42141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":42141,"derivative":{"exercise_price":2.068,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":42141},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444434,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":4517,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4517,"derivative":{"exercise_price":2.068,"exercise_date":"2022-01-03","expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":4517},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444433,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":197610,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":197610,"derivative":{"exercise_price":1.88,"exercise_date":"2022-01-03","expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":197610},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2494353,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-11-26T18:30:47.000Z","date":"2021-11-23","kind":"purchase","acquired":true,"shares":20000,"price":2.4,"value":48000.0,"ownership":{"direct":true},"balance_after":59512,"source":{"system":"sec-edgar","filing":"0000905718-21-001541","document":"dermata_fm4nov232021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001541/dermata_fm4nov232021.xml","form_type":"4"}},{"id":2600564,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Warrant to Purchase Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":142857,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Reporting Person purchased 142,857 Units in the IPO at $7.00 per Unit Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":142857,"derivative":{"exercise_price":7,"exercise_date":"2021-08-17","expiration_date":"2026-08-17","underlying":"Common Stock","underlying_shares":142857},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600563,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Warrant to Purchase Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":27987,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":27987,"derivative":{"exercise_price":20.5,"exercise_date":"2016-11-15","expiration_date":"2026-03-14","underlying":"Common Stock","underlying_shares":27987},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600562,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1a Warrants","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":573750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"exercise_date":"2016-11-15","expiration_date":"2026-03-14","underlying":"Common Stock","underlying_shares":27987},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600561,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1 Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":1755622,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":85640},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600560,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1c Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":25582050,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1247904},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600559,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1b Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":3722500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":181585},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600558,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1a Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":2295000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":111951},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600557,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1d Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":2436657,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":361147},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600556,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1d Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":241325,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":35767},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600555,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1d Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":60240,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Meghan Proehl Wilder 2020 Irrevocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8928},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600554,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Series 1d Preferred Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":120481,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Allison Taylor Proehl 2020 Irrevocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17857},"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600553,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":142857,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Reporting Person purchased 142,857 Units in the IPO at $7.00 per Unit Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":152857,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600552,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":85640,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2905544,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600551,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":1247904,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2819904,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600550,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":181585,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1572000,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600549,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":111951,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1390415,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600548,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":361147,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1278464,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600547,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":35767,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":35767,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600546,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":8928,"ownership":{"direct":false,"nature":"By Meghan Proehl Wilder 2020 Irrevocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":8928,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600545,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":17857,"ownership":{"direct":false,"nature":"By Allison Taylor Proehl 2020 Irrevocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":17857,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600544,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2021-08-17T16:38:51.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":10000,"price":4.9631,"value":49631.0,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $5.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000905718-21-001094","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001094/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2669474,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:34:56.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-21-006928","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006928/section16.xml","form_type":"4"}},{"id":3148301,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-15T21:01:20.000Z","date":"2020-05-01","kind":"grant","acquired":true,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":500,"derivative":{"exercise_price":0.66,"exercise_date":"2021-05-01","expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001654954-20-005667","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495420005667/section16.xml","form_type":"4"}},{"id":3475951,"issuer":{"id":152909,"kind":"organization","name":"SOPHIRIS BIO INC.","symbol":"SPHS"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-28T20:31:05.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Company 2017 Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period."}],"balance_after":20000,"derivative":{"exercise_price":0.7782,"exercise_date":"2019-07-27","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-039486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279191/000120919119039486/doc4.xml","form_type":"4"}},{"id":3553195,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-04-18T20:31:21.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":500,"derivative":{"exercise_price":6.23,"exercise_date":"2019-05-01","expiration_date":"2018-05-01","underlying":"Common stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001654954-19-004580","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495419004580/section16.xml","form_type":"4"}},{"id":3881274,"issuer":{"id":152909,"kind":"organization","name":"SOPHIRIS BIO INC.","symbol":"SPHS"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-28T20:59:46.000Z","date":"2018-06-27","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period."}],"balance_after":20000,"derivative":{"exercise_price":2.91,"exercise_date":"2018-07-27","expiration_date":"2028-06-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-039919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279191/000120919118039919/doc4.xml","form_type":"4"}},{"id":4089716,"issuer":{"id":7776,"kind":"organization","name":"FF EAI Robotics Ecosystem Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2018-01-26T02:31:23.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve (12) equal monthly installments beginning on February 23, 2018 with the balance vesting on the 23rd day of each calendar month thereafter until vested in full."}],"balance_after":30000,"derivative":{"exercise_price":0.34,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001382963-18-000023","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1460702/000138296318000023/edgar.xml","form_type":"4"}},{"id":4297888,"issuer":{"id":152909,"kind":"organization","name":"SOPHIRIS BIO INC.","symbol":"SPHS"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-01T20:35:05.000Z","date":"2017-05-30","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period."}],"balance_after":20000,"derivative":{"exercise_price":2.44,"exercise_date":"2017-06-30","expiration_date":"2027-05-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-036799","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279191/000120919117036799/doc4.xml","form_type":"4"}},{"id":4538701,"issuer":{"id":7776,"kind":"organization","name":"FF EAI Robotics Ecosystem Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (2015 Equity Incentive Plan)","published_at":"2016-11-30T23:46:53.000Z","date":"2016-11-29","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Of the 7,000 shares granted, 730 shares were vested as of the grant date and the remaining 6,270 shares will vest ratably over the next 43 months."}],"balance_after":7000,"derivative":{"exercise_price":2.37,"expiration_date":"2026-11-29","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001382963-16-000267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1460702/000138296316000267/edgar.xml","form_type":"4"}},{"id":4540734,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-11-29T20:55:57.000Z","date":"2016-11-23","kind":"purchase","acquired":true,"shares":14449,"price":1.76,"value":25430.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.73 to $1.79."}],"balance_after":29882,"source":{"system":"sec-edgar","filing":"0001354488-16-008600","document":"issuerdirect_section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000135448816008600/issuerdirect_section16.xml","form_type":"4"}},{"id":4540733,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-11-29T20:55:57.000Z","date":"2016-11-22","kind":"purchase","acquired":true,"shares":15433,"price":1.59,"value":24538.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.65. The reporting person undertakes to provide to Tenax Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":15433,"source":{"system":"sec-edgar","filing":"0001354488-16-008600","document":"issuerdirect_section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000135448816008600/issuerdirect_section16.xml","form_type":"4"}}]}